Renaissance Capital logo

TSBX News

Updated: Renaissance Capital's 3Q 2023 US IPO Market Review

Turnstone Biologics logo

Large Tech IPOs Stage a Comeback in a Volatile 3Q The third quarter of 2023 produced 30 IPOs that raised a combined $7.8 billion, more than the proceeds raised in the full-year 2022 despite no...read more

Renaissance Capital's July IPO Market Update

Turnstone Biologics logo

Eleven issuers raised a combined $939 million in July, well below the 10-year average (22 IPOs, $5.1B). Four deals raised $80 million or more, along with the year’s first direct listing (SRFM), and a wave of small issuers, which have largely disappeared...read more

US IPO Weekly Recap: ODDITY jumps 50% to become the IPO market’s latest beauty queen

ODD

Three IPOs priced this past week, led by the latest consumer success story, ODDITY Tech (ODD). DTC retailer ODDITY Tech priced above the raised range to raise $424 million at a $2.2 billion market cap. ODDITY’s current...read more

Solid tumor biotech Turnstone Biologics prices IPO at $12, the low end of the range

Turnstone Biologics logo

Turnstone Biologics, a Phase 1 biotech developing selected TIL therapies for solid tumors, raised $80 million by offering 6.7 million shares at $12, the low end of the range of $12 to $14. The company offered 0.9 million more shares than anticipated. Takeda had...read more